股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | 請見備注 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位及業績股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年9月30 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百三十七名承授人授 出涉及合共36,234股美國存託股份的受限制股份單位，並向一名承授人授出涉及 合共2,935股美國存託股份的業績股份單位。 2016期權及激勵計劃項下的受限制股份單位及業績股份單位 於2025年9月30日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 三十七名承授人合共36,234股美國存託股份受限制股份單位，並向一名承授人授 出合共2,935股美國存託股份業績股份單位。該等受限制股份單位及業績股份單位 相當於509,197股股份，約佔本公告之日公司發行股份總數的0.03%。 ...

Core Viewpoint - Pharmacyclics LLC has decided not to appeal the final written decision from the USPTO regarding the patent dispute with BeiGene, leading to the voluntary withdrawal of the lawsuit by both parties [1][4]. Group 1: Legal Proceedings - On June 13, 2023, Pharmacyclics filed a lawsuit against BeiGene and its subsidiary BeOne Medicines USA, claiming that the product Brukinsa infringed on its US patent No. 11,672,803 [4]. - The court agreed to suspend the infringement lawsuit pending the outcome of BeiGene's application for a post-grant review (PGR) of the '803 patent, which is due by November 1, 2023 [4]. - On April 29, 2025, the USPTO declared the '803 patent invalid, and Pharmacyclics had the option to appeal this decision [4][5]. Group 2: Financial Performance - In the first half of 2025, BeiGene reported total revenue of 17.518 billion yuan, a year-on-year increase of 46.0%, and achieved a net profit of 450 million yuan, compared to a loss of 2.877 billion yuan in the same period last year [7]. - The majority of BeiGene's revenue came from international markets, with overseas sales of Brukinsa reaching 11.335 billion yuan, accounting for 65.3% of total revenue, while sales in China were 1.192 billion yuan [7]. Group 3: Historical Financials - From 2017 to 2020, BeiGene experienced significant net losses, with figures of 982 million yuan, 4.747 billion yuan, 6.915 billion yuan, and 11.384 billion yuan respectively [5]. - The company continued to incur losses from 2021 to 2023, with net losses of 9.748 billion yuan, 13.642 billion yuan, and 6.716 billion yuan [5].

A 股代码：688235 A 股简称：百济神州 公告编号：2025-036 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次诉讼的基本情况及最新进展 2023 年 6 月 13 日，Pharmacyclics LLC 公司（作为申诉方，以下简称 "Pharmacyclics"）在美国特拉华州地方法院对百济神州有限公司（以下简称 "公司"）及公司全资子公司 BeOne Medicines USA, Inc（. 前称 BeiGene USA, Inc.） （作为被申诉方）提出申诉，声称公司产品百悦泽®侵犯了其于 2023 年 6 月 13 日授权的美国专利编号为 11,672,803 的专利（以下简称"'803 专利"），并请 1 案件所处的诉讼阶段：双方已向法院提交一份共同协议，自愿撤回案件， 案件已做出终局处理。 公司所处的当事人地位：本次诉讼的被申诉方。 是否会对公司损益产生负面影响：本次诉讼 ...

（原标题：寻找"受尊敬"企业系列报道之五：1.62万亿元研发投入构筑A股上市公司发展"护城河"） 科技是第一生产力，科技创新成为现阶段转型发展的关键。当前，我们正经历百年未有之大变局，这个变局的"始作俑者"就是日新月异的科技进 步。今天，以新一代信息技术、机器人、人工智能、生命科学、新能源等为代表的科技革命正重塑产业、经济格局，科技竞争已经成为各方博弈 的重要方面。 对于企业而言，科技创新不仅是评价一个企业综合实力以及保持高质量发展的重要指标和核心推动力，还是衡量一个企业能否受到普遍尊敬，以 及能否负责任地扛起行业创新大旗的重要体现。由经济观察报主办的2024—2025年度"寻找'受尊敬'企业"征集评选工作以"智创未来，向新而行"为 主题，也彰显了科技创新的独特分量。 从公司来看，比亚迪（002594.SZ）2024年以531.95亿元研发费用居首，研发投入同比增加超过百亿元，被称为"研发之王"；中国电建 （601669.SH）2024年研发投入242.5亿元，排在第二位；中国石油（601857.SH）、宁德时代（300750.SZ）、美的集团（000333.SZ）、中国中车 （601766.SH）、中国石化 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 請參閱百濟神州有限公司（「百濟神州」或「本公司」）於2023年6月16日和2025年4 月30日就Pharmacyclics LLC（「Pharmacyclics」）發起的專利侵權指控發佈的公告。 本公司宣佈，Pharmacyclics決定不對美國專利商標局的最終書面決定提起上 訴，該最終書面決定宣布Pharmacyclics在專利授權後複審程序中受到百濟神 州質疑的第11,672,803號美國專利（「'803專利」）的全部權利無效。百濟神州和 Pharmacyclics於2025年9月30日（美國時間）向相關地方法院提交一份共同協議， 自願撤回訴訟案件，案件已做出終局處理。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年10月2日 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 於本公告日期，本公司董事會包括主席兼執 ...

Market Sector - The Sci-Tech Innovation Board (STAR Market) index increased by 51.20% in the first three quarters of 2025, ranking second among various sector indices, outperforming the North Exchange 50, Shenzhen 50, and Shanghai 50 indices [2] - As of the end of Q3 2025, the total market capitalization of the STAR Market reached 10.95 trillion yuan, an increase of 3.33 trillion yuan from 7.62 trillion yuan at the end of Q2 2025, representing a growth rate of 43.66%, which is higher than other sectors [4] - The total trading volume of the STAR Market reached 25.93 trillion yuan in the first three quarters of 2025, with an average trading volume of 440.32 billion yuan per stock, which is lower than the average trading volumes of stocks in the Shanghai and Shenzhen main boards and the ChiNext [6] - The average daily turnover rate of the STAR Market was 2.99% in the first three quarters of 2025, higher than that of the Shanghai main board but lower than that of the Shenzhen main board, ChiNext, and North Exchange [8] - The price-to-book ratio of the STAR Market was 5.78 times at the end of Q3 2025, higher than that of the ChiNext and Shanghai and Shenzhen main boards [11] - The financing balance of the STAR Market reached 244.335 billion yuan at the end of Q3 2025, an increase of 99.034 billion yuan from 145.301 billion yuan at the beginning of the year [13] - The margin trading balance of the STAR Market was 0.829 billion yuan at the end of Q3 2025, an increase of 0.037 billion yuan from 0.459 billion yuan at the beginning of the year [15] Individual Stocks - As of the end of Q3 2025, SMIC led with a market capitalization exceeding 700 billion yuan, followed by Haiguang Information, Cambricon Technologies, and BeiGene, with 11 companies having market capitalizations exceeding 100 billion yuan [18] Industry Themes - In the first three quarters of 2025, companies listed on the STAR Market were primarily distributed across three Wind Sci-Tech theme industries, with the new generation information technology industry leading with four companies, followed by high-end equipment manufacturing and biotechnology industries, each with one company [29] - Among the seven companies issued on the STAR Market in the first three quarters of 2025, six were listed under Standard One, which requires positive net profits for the last two years and a cumulative net profit of no less than 50 million yuan, or a positive net profit for the last year with operating income of no less than 100 million yuan, and an expected market capitalization of no less than 1 billion yuan [31] - The companies issued on the STAR Market in the first three quarters of 2025 came from Beijing and Jiangsu (two each), and Hubei, Zhejiang, and Guangdong (one each) [34] - The total IPO financing on the STAR Market in the first three quarters of 2025 was 7.901 billion yuan, a year-on-year decrease of 9.99%, with three companies raising over 1 billion yuan, three raising between 500 million to 1 billion yuan, and one raising less than 500 million yuan [36] - Yitang Co., Ltd. led the IPO financing in the first three quarters of 2025 with 2.497 billion yuan, while Yingshi Innovation and Xingfu Electronics each raised over 1 billion yuan [40]

中邮证券研报指出，百济神州上半年实现归母净利润4.5亿元（去年同期为-28.8亿元）、25Q2实现归母 净利润5.4亿元（去年同期为-9.7亿元）。公司同时将全年收入指引从此前的49-53 亿美元上调至50-53亿 美元、全年GAAP经营利润为正的指引不变。25Q2 泽布替尼环比稳定增长，地舒单抗快速放量。公司 为创新药出海龙头企业，全球商业化能力突出、在研管线即将进入收获期，首次覆盖，给予"买入"评 级。 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][9]. Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2025, with total revenue reaching 17.52 billion yuan, a 46% increase year-on-year, and a net profit of 450 million yuan compared to a loss of 2.88 billion yuan in the same period last year [5][6]. - The company has raised its full-year revenue guidance from 4.9-5.3 billion USD to 5-5.3 billion USD, while maintaining its guidance for positive GAAP operating profit for the year [5][6]. Financial Performance - In Q2 2025, the company achieved a revenue of 9.47 billion yuan, a 42.7% increase year-on-year, and a net profit of 540 million yuan, compared to a loss of 970 million yuan in the same quarter last year [5][6]. - The global revenue for the drug Zebutinib reached 1.74 billion USD in the first half of 2025, with a year-on-year growth of 54.7%, driven by strong performance in the US and Europe [6][7]. Product Development - The company is advancing its product pipeline, with several key trials underway, including a Phase III trial for a combination therapy involving Zebutinib [7][8]. - The company anticipates significant data releases in the second half of 2025 for various products, including a KRAS inhibitor and ADCs [8]. Earnings Forecast - The company is projected to achieve revenues of 37.1 billion yuan, 47.15 billion yuan, and 58.18 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding net profits of 820 million yuan, 4.07 billion yuan, and 8.07 billion yuan [9][11].

Core Viewpoint - BeiGene's stock price has shown significant volatility and growth in 2023, with a notable increase in revenue and net profit for the first half of the year [2][3]. Stock Performance - As of September 30, BeiGene's stock rose by 2.02% to 307.09 CNY per share, with a trading volume of 5.59 billion CNY and a market capitalization of 473.13 billion CNY [1]. - Year-to-date, BeiGene's stock price has increased by 90.72%, with a 1.17% rise in the last five trading days, a 5.47% decline over the past 20 days, and a 37.62% increase over the last 60 days [2]. Financial Performance - For the period from January to June 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million CNY, up 115.63% year-on-year [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for BeiGene was 23,300, a decrease of 3.90% from the previous period, with an average of 4,976 circulating shares per shareholder, an increase of 4.11% [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A and a decrease in holdings by Wan Jia You Xuan [3].